OmniAb Q1 net loss narrows to $7.7 million; revenue rises to $14.4 million

OmniAb, Inc.

OABI

0.00

OmniAb posted Q1 2026 revenue of $14.4 million, up from $4.2 million a year earlier, as license and milestone revenue rose on higher milestone revenue.
Net loss narrowed to $7.7 million, or $0.06 per share, from $18.2 million, or $0.17 per share, a year earlier.
Costs and operating expenses edged down to $22.3 million from $23.0 million, while cash costs and operating expenses fell to $12.3 million from $14.7 million.
Active partners totaled 107 as of March 31, with active programs at 409; active clinical programs and approved products stood at 32.
2026 total revenue guidance was raised to $28 million-$33 million, with year-end cash balance expected at $33 million-$38 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OmniAb Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.